Actively Recruiting
Liquid Biopsy in Mature B-cell Tumors
Led by Oncology Institute of Southern Switzerland · Updated on 2023-11-01
444
Participants Needed
1
Research Sites
539 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.
CONDITIONS
Official Title
Liquid Biopsy in Mature B-cell Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female adults 18 years or older
- Documented diagnosis of mature B-cell tumor according to WHO 2008 criteria
- Willing and able to comply with scheduled study procedures
- Evidence of a signed informed consent
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Oncology Research
Bellinzona, Canton Ticino, Switzerland, 6500
Actively Recruiting
Research Team
D
Davide Rossi, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here